Skip to main content
SpringerLink
Log in

Modernes Netzwerken

Thematische Ausrichtungen in der Arbeitsgruppe „Blasenkarzinom Experimentell“ der GeSRU Academics

Modern networks

Topics in the working group “Bladder cancer research” of the GeSRU Academics

  • Übersichten
  • Published:
Der Urologe Aims and scope Submit manuscript

Zusammenfassung

Im Januar 2015 wurde im Rahmen der Gründung der GeSRU Academics die Forschergruppe „Blasenkarzinom Experimentell“ initiiert. Eine der grundlegenden Herausforderungen, um in einem Netzwerkverbund produktiv arbeiten zu können, ist das Herausarbeiten thematischer und methodischer Expertise als Voraussetzung für gemeinsame Projekte. Daher war es der Gruppe ein erstes Anliegen, die Forschungsschwerpunkte einzelner Mitglieder zu bündeln und darzustellen, um im Anschluss aktuelle Fragestellungen zu formulieren. Im folgenden Übersichtsbeitrag werden drei Themenkomplexe erläutert, die eine hohe Aufmerksamkeit an verschiedenen Standorten in Deutschland erfahren und daher in Verbundprojekte münden sollen.

Abstract

In January 2015, the research group “bladder cancer research” was founded as part of the GeSRU Academics research initiative. A general challenge to work successfully in a novel network structure is to identify common scientific topics and technical expertise in the group. Thus, one of the first tasks was to learn about current research projects from members within the group in order to address a project that suits the group’s expertise. The following review summarizes three different directions that are key projects in Urologic Departments at German Universities that will be the basis to start fruitful collaborations.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1

Literatur

  1. Krol J, Loedige I, Filipowicz W (2010) The widespread regulation of microRNA biogenesis, function and decay. Nat Rev Genet 11(9):597–610

    CAS  PubMed  Google Scholar 

  2. Zhang Y, Yang P, Wang XF (2014) Microenvironmental regulation of cancer metastasis by miRNAs. Trends Cell Biol 24(3):153–160

    Article  CAS  PubMed  Google Scholar 

  3. Penfornis P et al (2016) Extracellular vesicles as carriers of microRNA, proteins and lipids in tumor microenvironment. Int J Cancer 138(1):14–21

    Article  CAS  PubMed  Google Scholar 

  4. Matullo G, Naccarati A, Pardini B (2016) MicroRNA expression profiling in bladder cancer: the challenge of next-generation sequencing in tissues and biofluids. Int J Cancer 138(10):2334–2345

    Article  CAS  PubMed  Google Scholar 

  5. Adam L et al (2009) miR-200 expression regulates epithelial-to-mesenchymal transition in bladder cancer cells and reverses resistance to epidermal growth factor receptor therapy. Clin Cancer Res 15(16):5060–5072

    Article  CAS  PubMed  Google Scholar 

  6. Fujii T et al (2015) microRNA-145 promotes differentiation in human urothelial carcinoma through down-regulation of syndecan-1. BMC Cancer 15:818

    Article  PubMed  PubMed Central  Google Scholar 

  7. Chiyomaru T et al (2010) miR-145 and miR-133 a function as tumour suppressors and directly regulate FSCN1 expression in bladder cancer. Br J Cancer 102(5):883–891

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Wu Z et al (2015) Upregulation of microRNA-96 and its oncogenic functions by targeting CDKN1A in bladder cancer. Cancer Cell Int 15:107

    Article  PubMed  PubMed Central  Google Scholar 

  9. Xiu Y et al (2014) MicroRNA-137 upregulation increases bladder cancer cell proliferation and invasion by targeting PAQR3. PLOS ONE 9(e109734):10

    PubMed Central  Google Scholar 

  10. Tran MN et al (2013) The p63 protein isoform DeltaNp63alpha inhibits epithelial-mesenchymal transition in human bladder cancer cells: role of MIR-205. J Biol Chem 288(5):3275–3288

    Article  CAS  PubMed  Google Scholar 

  11. Catto JW et al (2009) Distinct microRNA alterations characterize high- and low-grade bladder cancer. Cancer Res 69(21):8472–8481

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Zhou H et al (2015) A panel of eight-miRNA signature as a potential biomarker for predicting survival in bladder cancer. J Exp Clin Cancer Res 34:53

    Article  PubMed  PubMed Central  Google Scholar 

  13. Mengual L et al (2013) Using microRNA profiling in urine samples to develop a non-invasive test for bladder cancer. Int J Cancer 133(11):2631–2641

    CAS  PubMed  Google Scholar 

  14. Fang Z et al (2016) Circulating miR-205: a promising biomarker for the detection and prognosis evaluation of bladder cancer. Tumour Biol 37(6):8075–8082

    Article  CAS  PubMed  Google Scholar 

  15. Cheng Y et al (2015) Urine microRNAs as biomarkers for bladder cancer: a diagnostic meta-analysis. Onco Targets Ther 8:2089–2096

    PubMed  PubMed Central  Google Scholar 

  16. Zhang X et al (2015) MicroRNA-203 is a prognostic indicator in bladder cancer and enhances chemosensitivity to cisplatin via apoptosis by targeting Bcl-w and Survivin. PLOS ONE 10(e0143441):11

    Google Scholar 

  17. Papadopoulos EI, Scorilas A (2015) Cisplatin and paclitaxel alter the expression pattern of miR-143/145 and miR-183/96/182 clusters in T24 bladder cancer cells. Clin Transl Sci 8(6):668–675

    Article  CAS  PubMed  Google Scholar 

  18. Li Y et al (2015) The miR-193 a-3p-regulated ING5 gene activates the DNA damage response pathway and inhibits multi-chemoresistance in bladder cancer. Oncotarget 6(12):10195–10206

    Article  PubMed  PubMed Central  Google Scholar 

  19. The Cancer Genome Atlas Research Network et al (2014) Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 507:315–322. doi:10.1038/nature12965

    Article  PubMed Central  Google Scholar 

  20. Knowles MA, Hurst CD (2015) Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity. Nat Rev Cancer 15(1):25–41

    Article  CAS  PubMed  Google Scholar 

  21. Forment JV, Kaidi A, Jackson SP (2012) Chromothripsis and cancer: causes and consequences of chromosome shattering. Nat Rev Cancer 12(10):663–670

    Article  CAS  PubMed  Google Scholar 

  22. Iyer G et al (2013) Prevalence and co-occurrence of actionable genomic alterations in high-grade bladder cancer. J Clin Oncol 31(25):3133–3140

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Sjodahl G et al (2013) Toward a molecular pathologic classification of urothelial carcinoma. Am J Pathol 183(3):681–691

    Article  CAS  PubMed  Google Scholar 

  24. Meena JK et al (2015) Telomerase abrogates aneuploidy-induced telomere replication stress, senescence and cell depletion. EMBO J 34(10):1371–1384

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Bettegowda C et al (2014) Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med 6(224):224ra24

    Article  PubMed  PubMed Central  Google Scholar 

  26. Dawson SJ et al (2013) Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med 368(13):1199–1209

    Article  CAS  PubMed  Google Scholar 

  27. Lecomte T et al (2002) Detection of free-circulating tumor-associated DNA in plasma of colorectal cancer patients and its association with prognosis. Int J Cancer 100(5):542–548

    Article  CAS  PubMed  Google Scholar 

  28. Reinert T et al (2016) Analysis of circulating tumour DNA to monitor disease burden following colorectal cancer surgery. Gut 65(4):625–634

    Article  PubMed  Google Scholar 

  29. Birkenkamp-Demtroder K et al (2016) Genomic alterations in liquid biopsies from patients with bladder cancer. Eur Urol 70(1):75–82

    Article  CAS  PubMed  Google Scholar 

  30. Heitzer E, Ulz P, Geigl JB (2015) Circulating tumor DNA as a liquid biopsy for cancer. Clin Chem 61(1):112–123

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Universitätsklinik für Urologie, Medizinische Universität Wien, Wien, Österreich

    S. Hofbauer

  2. Klinik und Poliklinik für Urologie und Kinderurologie, Universitätsklinikum Würzburg, Würzburg, Deutschland

    C. Kalogirou

  3. Universitätsklinik für Urologie, Marien Hospital Herne, Ruhr-Universität Bochum, Herne, Deutschland

    F. Roghmann

  4. Klinik und Poliklinik für Urologie, Klinikum rechts der Isar der TU-München, Ismaninger Str. 22, München, Deutschland

    A.-K. Seitz &  R. Nawroth

  5. Klinik für Urologie, Universitätsklinik Frankfurt, Goethe Universität Frankfurt, Frankfurt, Deutschland

    S. Vallo

  6. Klinik für Urologie und Kinderurologie, Universitätsklinikum Ulm, Ulm, Deutschland

    F. Wezel

  7. Klinik für Urologie, Universitätsmedizin Mannheim, Universität Heidelberg, Mannheim, Deutschland

    T. Worst

Authors
  1. S. Hofbauer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. C. Kalogirou
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. F. Roghmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A.-K. Seitz
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. S. Vallo
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. F. Wezel
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. T. Worst
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. R. Nawroth
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to R. Nawroth.

Ethics declarations

Interessenkonflikt

S. Hofbauer, C. Kalogirou, F. Roghmann, A.-K. Seitz, S. Vallo, F. Wezel, T. Worst und R. Nawroth geben an, dass kein Interessenkonflikt besteht.

Dieser Beitrag beinhaltet keine von den Autoren durchgeführten Studien an Menschen oder Tieren. Ethische Normen sind bei den eigenen zitierten Studien eingehalten worden.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hofbauer, S., Kalogirou, C., Roghmann, F. et al. Modernes Netzwerken. Urologe 56, 202–207 (2017). https://doi.org/10.1007/s00120-016-0217-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00120-016-0217-z

Schlüsselwörter

Keywords

Search

Navigation